| |
| | ag-ip-news.com (Intellectual Property News Agency)AGIPNEWS1367 |
 | | Barr's suit challenges FDA's policy of awarding generic exclusivity on a patent-by-patent basis, rather than solely to the first company to submit an application containing a paragraph IV certification to a listed patent, a press release by the Company stated. |
 | | Barr believes that FDA's policy is contrary to Hatch-Waxman, and that the company is entitled to sole exclusivity for its generic Allegra-D (fexofenadine hydrochloride and pseudoephedrine hydrochloride) tablet product. |
 | | Barr Pharmaceuticals, Inc., a holding company that operates through its principal subsidiaries, Barr Laboratories, Inc. and Duramed Pharmaceuticals, Inc., is engaged in the development, manufacture and marketing of generic and proprietary pharmaceuticals. |
| www.ag-ip-news.com /GetArticle.asp?Art_ID=1367 (331 words) |
|